News | November 01, 2024
Supriya Lifescience reports 19% revenue increase in Q2 FY25
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Potential of Ayurveda’s contribution in global health system through various innovative practices
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
Transform healthcare by integrating expertise from AI, clinical sciences, and basic sciences to harness India’s extensive data sets for improving the access to healthcare
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
Subscribe To Our Newsletter & Stay Updated
